Real-World data to reveal how lung cancer drug lorlatinib performs outside clinical trials

This study looks at how patients with a specific type of advanced lung cancer (ALK-positive non-small cell lung cancer) respond to the drug lorlatinib when it is used as their first treatment. Researchers will analyze information from a large database of 200 patients to see how long they stay on the drug, how often doses need to be changed, and what happens after they stop. The goal is to understand how well the medicine works in real life, outside of a controlled clinical trial.